Phase 2 safety and antiviral activity of SAB-185, a novel polyclonal antibody therapy for non-hospitalized adults with COVID-19

By sjmartinez • January 21, 2023

Taiwo BO, Chew KW, Moser C, Wohl DA, Daar ES, Li JZ, Greninger AL, Bausch C, Luke T, Hoover K, Neytman G, Giganti MJ, Olefsky M, Javan AC, Fletcher CV, Eron JJ, Currier JS, Hughes MD, Smith DM; ACTIV-2/A5401 Study Team. Phase 2 safety and antiviral activity of SAB-185, a novel polyclonal antibody therapy for non-hospitalized adults with COVID-19. J Infect Dis. 2023 Jan 20:jiad013. doi: 10.1093/infdis/jiad013. Epub ahead of print. PMID: 36661240.

Tags: antibody, covid-19, Infectious Diseases, polyclonal, Publications, SAB-185, transchromosomic, Treatment

Severe outcomes of individual or multiple respiratory viral infections in a large national healthcare system, 2022-2023

Grubber JM, Oboho IK, Swinnerton KN, Feldman TC, Do NV, Fillmore NR, Branch-Elliman W, Monach PA. Severe outcomes of individual or multiple respiratory viral infections[...]

Incidence, risk factors, and cardiovascular impact of hypertension in people with HIV: a secondary analysis of the REPRIEVE trial

Martínez E, Watanabe M, Hoffman R, Zanni MV, Pozniak A, Shakil SS, McCallum S, Chu SM, Srinivasa S, Malvestutto CD, Fichtenbaum CJ, Bloomfield GS, Sponseller[...]

Missed Opportunities for HIV and Syphilis Co-Testing in Emergency Departments

Sherwood K, Zhang N, David H, Dekker A, Garner O, Samuels E, Adamson P. Missed Opportunities for HIV and Syphilis Co-Testing in Emergency Departments. Clin[...]